Cost-effectiveness of a new rotavirus vaccination program in Pakistan: A decision tree model

被引:16
|
作者
Patel, Hiten D. [1 ,2 ]
Roberts, Eric T. [3 ]
Constenla, Dagna O. [4 ]
机构
[1] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
关键词
Rotavirus; Gastroenteritis; Cost-effectiveness; Vaccination; Pakistan; GLOBAL BURDEN; DISEASE; CHILDREN; GASTROENTERITIS; SURVEILLANCE; EFFICACY; HEALTH; IMPACT; IMMUNIZATION; STRATEGIES;
D O I
10.1016/j.vaccine.2013.10.022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Rotavirus gastroenteritis places a significant health and economic burden on Pakistan. To determine the public health impact of a national rotavirus vaccination program, we performed a cost-effectiveness study from the perspective of the health care system. Methods: A decision tree model was developed to assess the cost-effectiveness of a national vaccination program in Pakistan. Disease and cost burden with the program were compared to the current state. Disease parameters, vaccine-related costs, and medical treatment costs were based on published epidemiological and economic data, which were specific to Pakistan when possible. An annual birth cohort of children was followed for 5 years to model the public health impact of vaccination on health-related events and costs. The cost-effectiveness was assessed and quantified in cost (2012 US$) per disability-adjusted life-year (DALY) averted and cost per death averted. Sensitivity analyses were performed to assess the robustness of the incremental cost-effectiveness ratios (ICERs). Results: The base case results showed vaccination prevented 1.2 million cases of rotavirus gastroenteritis, 93,000 outpatient visits, 43,000 hospitalizations, and 6700 deaths by 5 years of age for an annual birth cohort scaled from 6% current coverage to DPT3 levels (85%). The medical cost savings would be US$1.4 million from hospitalizations and US$200,000 from outpatient visit costs. The vaccination program would cost US$35 million at a vaccine price of US$5.00. The ICER was US$149.50 per DALY averted or US$4972 per death averted. Sensitivity analyses showed changes in case-fatality ratio, vaccine efficacy, and vaccine cost exerted the greatest influence on the ICER. Conclusions: Across a range of sensitivity analyses, a national rotavirus vaccination program was predicted to decrease health and economic burden due to rotavirus gastroenteritis in Pakistan by similar to 40%. Vaccination was highly cost-effective in this context. As discussions of implementing the intervention intensify, future studies should address affordability, efficiency, and equity of vaccination introduction. 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6072 / 6078
页数:7
相关论文
共 50 条
  • [1] Rotavirus Disease Burden and Impact and Cost-Effectiveness of a Rotavirus Vaccination Program in Kenya
    Tate, Jacqueline E.
    Rheingans, Richard D.
    O'Reilly, Ciara E.
    Obonyo, Benson
    Burton, Deron C.
    Tornheim, Jeffrey A.
    Adazu, Kubaje
    Jaron, Peter
    Ochieng, Benjamin
    Kerin, Tara
    Calhoun, Lisa
    Hamel, Mary
    Laserson, Kayla
    Breiman, Robert F.
    Feikin, Daniel R.
    Mintz, Eric D.
    Widdowson, Marc-Alain
    JOURNAL OF INFECTIOUS DISEASES, 2009, 200 : S76 - S84
  • [2] Cost-effectiveness of rotavirus vaccination in Turkey
    Koksal, Tulin
    Akelma, Ahmet Zulfikar
    Koksal, Ali Osman
    Kutukoglu, Irem
    Ozdemir, Osman
    Yuksel, Cigdem Nuket
    Bozkaya, Davut
    Catal, Ferhat
    Sari, Sinan
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2017, 50 (05) : 693 - 699
  • [3] Cost-effectiveness of Rotavirus vaccination in Vietnam
    Sun-Young Kim
    Sue J Goldie
    Joshua A Salomon
    BMC Public Health, 9
  • [4] The cost-effectiveness of rotavirus vaccination in Belgium
    Bilcke, J.
    Beutels, P.
    Van Damme, P.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2007, 17 : 179 - 180
  • [5] Cost-effectiveness of Rotavirus vaccination in Vietnam
    Kim, Sun-Young
    Goldie, Sue J.
    Salomon, Joshua A.
    BMC PUBLIC HEALTH, 2009, 9
  • [6] Cost-effectiveness of rotavirus vaccination in Mozambique
    Guimaraes, Esperanca Lourenco
    Chissaque, Assucenio
    Pecenka, Clint
    Clark, Andrew
    Vaz, Basilia
    Banze, Arlindo
    Canana, Neide
    Romao, Clesio
    Martins, Maria do Rosario Oliveira
    de Deus, Nilsa
    Debellut, Frederic
    VACCINE, 2022, 40 (36) : 5338 - 5346
  • [7] Cost-effectiveness of rotavirus vaccination in Albania
    Ahmeti, Albana
    Preza, Iria
    Simaku, Artan
    Nelaj, Erida
    Clark, Andrew David
    Garcia, Ana Gabriela Felix
    Lara, Carlos
    Hoestlandt, Celine
    Blau, Julia
    Bino, Silvia
    VACCINE, 2015, 33 : A201 - A208
  • [8] The cost-effectiveness of rotavirus vaccination in Armenia
    Jit, Mark
    Yuzbashyan, Ruzanna
    Sahakyan, Gayane
    Avagyan, Tigran
    Mosina, Liudmila
    VACCINE, 2011, 29 (48) : 9104 - 9111
  • [9] Cost-Effectiveness of Rotavirus Vaccination in Peru
    Clark, Andrew D.
    Walker, Damian G.
    Rocio Mosqueira, N.
    Penny, Mary E.
    Lanata, Claudio F.
    Fox-Rushby, Julia
    Sanderson, Colin F. B.
    JOURNAL OF INFECTIOUS DISEASES, 2009, 200 : S114 - S124
  • [10] The cost-effectiveness of rotavirus vaccination in Australia
    Newall, Anthony T.
    Beutels, Philippe
    Macartney, Kristine
    Wood, James
    MacIntyre, C. Raina
    VACCINE, 2007, 25 (52) : 8851 - 8860